← Back to Analyst Consensus 
PVLA Buy
PALVELLA THERAPEUTICS, INC.
Current Price —
Implied Upside —
Analysts 22
30-Day Momentum
▲ 1 upgrades / ▼ 0 downgrades / 1 reiterations from 2 firms
Next Earnings
Nov 17, 2026 (22 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Oct 16, 2026 | William Blair | initiate | — → Outperform | — | 48% |
| Oct 12, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| Sep 21, 2026 | Chardan Capital | maintain | Buy → Buy | — | 47% |
| May 21, 2026 | Stephens & Co. | reiterate | Overweight → Overweight | — | 54% |
| May 21, 2026 | Chardan Capital | maintain | Buy → Buy | — | 47% |
| May 12, 2026 | Stephens & Co. | initiate | — → Overweight | — | 54% |
| Mar 31, 2026 | Chardan Capital | maintain | Buy → Buy | — | 47% |
| Mar 24, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| Mar 16, 2026 | Chardan Capital | maintain | Buy → Buy | — | 47% |
| Feb 25, 2026 | Mizuho | maintain | Outperform → Outperform | $250 | 52% |
| Feb 25, 2026 | BTIG | maintain | Buy → Buy | $215 | 52% |
| Feb 24, 2026 | Chardan Capital | maintain | Buy → Buy | $210 | 47% |
| Feb 24, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | $255 | 44% |
| Jan 29, 2026 | BTIG | reiterate | Buy → Buy | $192 | 52% |
| Jan 16, 2026 | BTIG | reiterate | Buy → Buy | $192 | 52% |
| Jan 7, 2026 | Mizuho | initiate | — → Outperform | $205 | 52% |
| Dec 16, 2025 | Truist Securities | maintain | Buy → Buy | $190 | 54% |
| Dec 16, 2025 | Canaccord Genuity | maintain | Buy → Buy | $204 | 48% |
| Dec 16, 2025 | TD Cowen | maintain | Buy → Buy | $133 | 54% |
| Dec 16, 2025 | Chardan Capital | maintain | Buy → Buy | $174 | 47% |
| Dec 15, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $200 | 44% |
| Dec 15, 2025 | BTIG | maintain | Buy → Buy | $192 | 52% |
| Dec 5, 2025 | Clear Street | initiate | — → Buy | $200 | 49% |
| Dec 5, 2025 | BTIG | initiate | — → Buy | $167 | 52% |
| Dec 4, 2025 | Craig-Hallum | initiate | — → Buy | $175 | 54% |
| Nov 24, 2025 | Stifel | maintain | Buy → Buy | $145 | 53% |
| Nov 19, 2025 | Raymond James | upgrade | Outperform → Strong Buy | $143 | 54% |
| Nov 13, 2025 | Canaccord Genuity | maintain | Buy → Buy | $148 | 48% |
| Nov 13, 2025 | Chardan Capital | maintain | Buy → Buy | $110 | 47% |
| Nov 10, 2025 | Truist Securities | maintain | Buy → Buy | $105 | 54% |
| Nov 7, 2025 | Chardan Capital | maintain | Buy → Buy | $110 | 47% |
| Nov 6, 2025 | TD Cowen | maintain | Buy → Buy | $97 | 54% |
| Nov 6, 2025 | Cantor Fitzgerald | maintain | Overweight → Overweight | $200 | 50% |
| Nov 6, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $190 | 44% |
| Oct 9, 2025 | Canaccord Genuity | maintain | Buy → Buy | $90 | 48% |
| Oct 2, 2025 | Truist Securities | maintain | Buy → Buy | $80 | 54% |
| Sep 26, 2025 | Chardan Capital | maintain | Buy → Buy | $73 | 47% |
| Sep 25, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $95 | 44% |
| Sep 24, 2025 | Stifel | maintain | Buy → Buy | $80 | 53% |
| Sep 9, 2025 | Oppenheimer | initiate | — → Outperform | $85 | 52% |
| Aug 19, 2025 | Canaccord Genuity | maintain | Buy → Buy | $66 | 48% |
| Aug 15, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $75 | 44% |
| Aug 15, 2025 | Chardan Capital | maintain | Buy → Buy | $60 | 47% |
| Aug 6, 2025 | Raymond James | initiate | — → Outperform | $54 | 54% |
| Aug 4, 2025 | LifeSci Capital | initiate | — → Outperform | $90 | 57% |
| Jul 21, 2025 | Truist Securities | initiate | — → Buy | $56 | 54% |
| May 16, 2025 | Canaccord Genuity | maintain | Buy → Buy | $52 | 48% |
| Apr 30, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $38 | 44% |
| Apr 9, 2025 | Chardan Capital | initiate | — → Buy | $50 | 47% |
| Apr 2, 2025 | Canaccord Genuity | maintain | Buy → Buy | $53 | 48% |
Price Target Trend
Jun 11, 2026 Oct 26, 2026
EPS Estimates
+1q —
+1y —
0y —
0q —
Cross-Platform Signals
No cross-platform signals in the last 90 days